search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
3 Silica Bonded Phases for Polar and Non-Polar Molecules


The Cogent TYPE-C™ silica bonded phases, manufactured by MicroSolv Technology Corporation (USA), have a surface populated by silicon-hydride functional groups instead of silanols. Patented bonding technology is then used to produce the Cogent Bidentate C18, Bidentate C8, UDC- Cholesterol, Phenyl and Diamond Hydride (the “Metabolomics Column”) phases, with direct silicon-carbon bonds on the silica hydride surface. These bonded phases have the ability to retain polar solutes at high concentrations of organic solvent by aqueous normal-phase (ANP). In addition, non-polar compounds can also be retained on the same column under reversed-phase conditions. The lack of surface silanols leads to fast equilibration times, excellent peak shape and extended column lifetimes for the assay of a wide range of pharmaceuticals, organic acids, carbohydrates, biochemicals, peptides, metabolites and many other compounds.


For further information and a technical brochure on Cogent TYPE-C silica HPLC columns, email Hichrom Limited at: technical@hichrom.co.uk or Tel: 0118 930 3660 or www.microsolvtech.com


High Pressure Ion Chromatography Speeds Separation of Counter Ions in a Drug Tablet


Thermo Fisher Scientific is pleased to announce a new technical note on the rapid separation and quantification of a pharmaceutical counter ion using increased flow rates on our high-pressure capillary Ion Chromatography system, the Thermo Scientific Dionex ICS-5000+ HPIC system. Technical Note 120: Fast Separations of Counter Ions in an Allergy Drug Tablet Using High-Pressure IC demonstrates the importance of counter ion determinations in order to confirm the correct stoichiometry and formula weight of a drug, and, also to test for drug impurities.


With the upgrade to high pressure, capillary systems can operate at system pressures up to 5000 psi. This advance in technology allows 2X to 3X the µL/min flow rates with all the same advantages as standard pressure capillary IC, resulting in low consumption of water (30 to 40 mL/d of water) and low waste generation. Capillary IC systems can remain on 24/7 with minimal resource consumption which translates into a system which has greater ease-of-use, a longer lasting eluent generator cartridge and a far more inexpensive cost of ownership associated with it.


This technical note and many others can be found at www.thermoscientific.com/dionex under the Documents tab.


Analysis of Nitrosamines in Malt for Beer & Whisky


In Brewing Barley undergoes a malting process, the grain if first drenched to make it germinate and then dried in kilns to capture the sugar and flavour compounds for the brewing process. The Heating in the kilns can cause the formation of carcinogenic nitrosamine compounds in the grain, these can then potentially be passed on to the final brewed product. It is therefor essential that any malt used in brewing is checked for nitrosamine levels.


The 800 Series Thermal Energy Analyser (TEA) has been an industry standard for nitrosamine analysis since its introduction thanks to its incredible sensitivity and almost infinite selectivity for nitrogen containing compounds. The 800 Series TEA can be interfaced with most common GCs.


For further information visit http://j.mp/MtXOfq


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60